Last reviewed · How we verify
NCT06314906
Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer
Phase 3 trial testing Electroacupuncture in Electroacupuncture in 370 participants. Currently enrolling.
31 January 2027
Quick facts
| Lead sponsor | Feixue Song |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 370 |
| Start date | 7 March 2024 |
| Primary completion | 31 January 2027 |
| Estimated completion | 31 March 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Electroacupuncture
- Antiemetic Therapy — full drug profile →
- Sham electroacupuncture
- Antiemetic Therapy — full drug profile →
Conditions studied
- Electroacupuncture — all drugs for Electroacupuncture →
- Olanzapine-contained Four-drug Antiemetic — all drugs for Olanzapine-contained Four-drug Antiemetic →
- Nausea and Vomiting — all drugs for Nausea and Vomiting →
Sponsor
Feixue Song — full company profile →
Who can join
Adults 18 to 75, any sex, with Electroacupuncture or Olanzapine-contained Four-drug Antiemetic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study explores the effectiveness of combining electroacupuncture with olanzapine-containing four-drug antiemetic therapy to mitigate chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer. The research aims to assess the adjunctive benefits of electroacupuncture in enhancing the antiemetic effects of conventional medication, particularly in the context of highly emetogenic chemotherapy regimens. By investigating the synergistic potential of these modalities, the study seeks to provide insights into optimizing supportive care strategies for patients with breast cancer undergoing intensive chemotherapy treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06314906
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Electroacupuncture
Trials testing the same drug.
- NCT07530042 — Efficacy of Electroacupuncture Combined With Auricular Acupressure for Chronic Low Back Pain. · NA · not yet recruiting
- NCT07509294 — Effect Of Electroacupuncture With Local Anesthesia On Pain And Stress During Impacted Lower Third Molar Surgery · NA · not yet recruiting
- NCT07515027 — Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung · NA · recruiting
- NCT07487532 — Acupuncture for Preventing Atrial Arrhythmia Recurrence After Ablation · NA · not yet recruiting
- NCT07489625 — Hydromorphone With Electroacupuncture and Ear Acupoint Pressing for Refractory Cancer Pain · EARLY_PHASE1 · not yet recruiting
Other recruiting trials for Electroacupuncture
Currently open trials in the same condition.
- NCT07239661 — Electroacupuncture Combined With PD-1 Inhibitor for ECOG2 Advanced NSCLC · NA · recruiting
- NCT06952920 — Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer · Phase 3 · recruiting
- NCT07086300 — Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLC · NA · recruiting
- NCT06890260 — The Treatment of Moderate to Severe Allergic Rhinitis With Electroacupuncture Combined With Microneedle Knife · NA · recruiting
- NCT07034326 — Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-smal · Phase 2, PHASE3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06314906 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Feixue Song
- Last refreshed: 21 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06314906.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing